[Effectiveness of using recombinant interferon alfa2 (reaferon) combined with antioxidants in children with acute hepatitis B]. 1992

A R Reĭzis, and V V Malinovskaia, and S Shekhade, and A K Drondina, and T S Nikitina, and A S Markarian, and I V Nazarenko, and M I Mikhaĭlov

The authors describe the results of the first experience gained with the use of recombinant alpha 2-interferon in children with acute viral hepatitis B. The drug was administered rectally in combination with antioxidants (tocopherol). The study was carried out by the double blind method with randomization and two control groups (given tocopherol alone or placebo alone). 73 children with acute viral hepatitis B were examined. The therapeutic combination reaferon plus tocopherol was established to favour more rapid elimination of dyspeptic and abdominal phenomena, to shorten the time of the liver and spleen size increase, duration of hyperfermentemia, to provide for an accelerated reduction of HBsAg titers, elimination of HBeAg and seroconversion, to stimulate alpha-interferon production by leukocytes, and to activate the system of mononuclear phagocytes.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A R Reĭzis, and V V Malinovskaia, and S Shekhade, and A K Drondina, and T S Nikitina, and A S Markarian, and I V Nazarenko, and M I Mikhaĭlov
January 1988, Terapevticheskii arkhiv,
A R Reĭzis, and V V Malinovskaia, and S Shekhade, and A K Drondina, and T S Nikitina, and A S Markarian, and I V Nazarenko, and M I Mikhaĭlov
January 1992, Pediatriia,
A R Reĭzis, and V V Malinovskaia, and S Shekhade, and A K Drondina, and T S Nikitina, and A S Markarian, and I V Nazarenko, and M I Mikhaĭlov
September 1990, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
A R Reĭzis, and V V Malinovskaia, and S Shekhade, and A K Drondina, and T S Nikitina, and A S Markarian, and I V Nazarenko, and M I Mikhaĭlov
January 1995, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
A R Reĭzis, and V V Malinovskaia, and S Shekhade, and A K Drondina, and T S Nikitina, and A S Markarian, and I V Nazarenko, and M I Mikhaĭlov
January 1988, Lancet (London, England),
A R Reĭzis, and V V Malinovskaia, and S Shekhade, and A K Drondina, and T S Nikitina, and A S Markarian, and I V Nazarenko, and M I Mikhaĭlov
April 1988, Lancet (London, England),
A R Reĭzis, and V V Malinovskaia, and S Shekhade, and A K Drondina, and T S Nikitina, and A S Markarian, and I V Nazarenko, and M I Mikhaĭlov
January 1989, Voprosy virusologii,
A R Reĭzis, and V V Malinovskaia, and S Shekhade, and A K Drondina, and T S Nikitina, and A S Markarian, and I V Nazarenko, and M I Mikhaĭlov
March 1991, Klinicheskaia meditsina,
A R Reĭzis, and V V Malinovskaia, and S Shekhade, and A K Drondina, and T S Nikitina, and A S Markarian, and I V Nazarenko, and M I Mikhaĭlov
February 1990, The American journal of gastroenterology,
A R Reĭzis, and V V Malinovskaia, and S Shekhade, and A K Drondina, and T S Nikitina, and A S Markarian, and I V Nazarenko, and M I Mikhaĭlov
January 1990, Terapevticheskii arkhiv,
Copied contents to your clipboard!